Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

2134 - Influence of HIF-2alpha deregulation and overexpression of VEGF ligands on the response to aflibercept: identification of predictive biomarkers

Date

11 Sep 2017

Session

Poster display session

Topics

Cytotoxic Therapy;  Cancers in Adolescents and Young Adults (AYA);  Translational Research

Presenters

Annette LARSEN

Citation

Annals of Oncology (2017) 28 (suppl_5): v22-v42. 10.1093/annonc/mdx363

Authors

A.K. LARSEN1, S. Thouroude2, L. Louadj2, M. Sabbah2, E. Dochy3, A. de Gramont4, J.A. Denis2, A. Bouygues2

Author affiliations

  • 1 Cancer Biology And Therapeutics, Centre De Recherche Saint-antoine, INSERM U938 and Université Pierre et Marie Curie (UPMC), Sorbonne Universités Paris, France, 75571 - Paris/FR
  • 2 Cancer Biology And Therapeutics, Centre De Recherche Saint-antoine, INSERM U938 and Université Pierre et Marie Curie (UPMC), Sorbonne Universités, Paris, France, Paris/FR
  • 3 Late Development Lead – R&d, Sanofi Genzyme, Bruxelles/BE
  • 4 Medical Oncology, Institut hospitalier Franco-Britannique/ Franco-British Institute, Levallois-Perret/FR
More

Resources

Abstract 2134

Background

Angiogenesis inhibitors are widely used for treatment of metastastic colorectal cancer. However, no predictive biomarkers are currently available for patient selection. Besides the tumor-associated endothelial cells, VEGF-signaling inhibitors target CRC cells that express VEGF as well as functional VEGFR1 receptors thereby mediating both paracrine and autocrine VEGF-signaling. The aims of this work is i) to establish the direct influence of aflibercept (Zaltrap®) that inhibits all three VEGFR1 ligands (VEGF-A, VEGF-B and PlGF) on CRC cells, ii) to identify tumor phenotypes associated with resistance to aflibercept in vitro and, iii) to extend these findings to human xenograft models.

Methods

A panel of 12 well-characterized CRC cell lines was used to establish the influence of VEGFR1 stimulation (VEGF-A, VEGF-B, PlGF) and inhibition (aflibercept) on VEGF-mediated tumor cell migration. Expression of VEGF ligands and receptors was determined by qRT-PCR and ELISA assays. The in vivo influence of aflibercept was determined in human xenograft models and complemented by IHC and Western blot analysis.

Results

Aflibercept inhibited the migration of most CRC cells under both normoxia and hypoxia including the highly sensitive HCT-116 cells. In contrast, LS174T cells did not respond to either aflibercept or to purified VEGF ligands. These cells expressed high levels of VEGF ligands and HIF2alpha, even under normoxia. Accordingly, aflibercept showed pronounced in vivo activity toward HCT-116 xenografts with 75% tumor growth inhibition but only 40% tumor growth inhibition toward LS174T tumors, compared to the corresponding vehicle controls. A similar trend was observed for bevacizumab with 41% tumor growth inhibition for HCT-116 and 32% inhibition for LS174T xenografts. IHC analysis of LS174T xenografts confirmed the strong expression of HIF2alpha and VEGF ligands as well as a modest inhibitory effect on the tumor-associated endothelia cells.

Conclusions

We here report that aflibercept has direct antimigratory effects on most CRC cells. Strong expression of HIF-2alpha and VEGF ligands was accompanied by aflibercept resistance in vitro as in vivo.

Clinical trial identification

Legal entity responsible for the study

INSERM U938 and Université Pierre et Marie Curie (UPMC), Sorbonne Universités, Paris, France

Funding

Sanofi-Genzyme

Disclosure

A.K. Larsen: This work was supported in part by Sanofi Genzyme. E. Dochy: Employed by Sanofi-Genzyme. A. de Gramont: This research is in part supported by Sanofi. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.